The administration of the TAT-GILZ fusion protein could reduce tissue edema and increase perfusion of the ischemic/reperfused kidney in mice with acute kidney injury (AKI), and improve the disruption of mitochondrial membrane potential and cell death in vitro (83, 84). This evidence concerns the gene TSC22D3 and acute kidney injury.